Research graph
References from Optimizing the ER Cutoff in HER2 ‐Positive Breast Cancer: ER ≥ 50% Predicts Low pCR Rates and Resistance to Antibody‐Drug Conjugates in the Neoadjuvant Setting. Local targets link to admitted publications; unresolved targets remain external evidence.
Distinct ER and PR Expression Patterns Significantly Affect the Clinical Outcomes of Early HER2‐Positive Breast Cancer: A Real‐World Analysis of 871 Patients Treated With Neoadjuvant Therapy
10.1016/j.breast.2024.103733 · 2024 · External reference
ER+/HER2+ Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER−/HER2+ Breast Cancer
10.1016/j.clbc.2019.02.001 · 2019 · External reference
Clinicopathological Characteristics, Treatment Patterns and Outcomes in Patients With HER2‐Positive Breast Cancer Based on Hormone Receptor Status: A Retrospective Study
10.1186/s12885-024-12974-4 · 2024 · External reference
Discordance of the PAM50 Intrinsic Subtypes Compared With Immunohistochemistry‐Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance
10.4143/crt.2018.342 · 2019 · External reference
Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2‐Positive Breast Cancer With Long‐Term Outcomes: A Meta‐Analysis
10.1001/jamaoncol.2015.6113 · 2016 · External reference
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer
10.1200/jco.22.02241 · 2023 · External reference
Estrogen/HER2 Receptor Crosstalk in Breast Cancer: Combination Therapies to Improve Outcomes for Patients With Hormone Receptor‐Positive/HER2‐Positive Breast Cancer
10.1038/s41523-023-00533-2 · 2023 · External reference
10.1200/jco.2025.43.16_suppl.501
10.1200/jco.2025.43.16_suppl.501 · External reference
Hormone‐Receptor Expression and Activity of Trastuzumab With Chemotherapy in HER2‐Positive Advanced Breast Cancer Patients
10.1002/cncr.26162 · 2012 · External reference
Effect of Level of Hormone‐Receptor Expression on Treatment Outcomes of “Triple‐Positive” Early‐Stage Breast Cancer
10.1007/s10549-020-05942-6 · 2021 · External reference
Trastuzumab Deruxtecan Plus Pertuzumab for HER2‐Positive Metastatic Breast Cancer
10.1056/nejmoa2508668 · 2025 · External reference
Trastuzumab Deruxtecan in Residual HER2‐Positive Early Breast Cancer
10.1056/nejmoa2514661 · 2025 · External reference
Neoadjuvant Trastuzumab Deruxtecan Alone or Followed by Paclitaxel, Trastuzumab, and Pertuzumab for High‐Risk HER2‐Positive Early Breast Cancer (DESTINY‐Breast11): A Randomised, Open‐Label, Multicentre, Phase 3 Trial
10.1016/j.annonc.2025.10.019 · 2025 · External reference
Breast Cancer—Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual
2017 · External reference
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
10.1200/jco.19.02309 · 2020 · External reference
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
10.5858/arpa.2018-0902-sa · 2018 · External reference
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
10.1093/jnci/djaa201 · 2021 · External reference
Alternative Preprocessing of RNA‐Sequencing Data in the Cancer Genome Atlas Leads to Improved Analysis Results
10.1093/bioinformatics/btv377 · 2015 · External reference
Invasive Lobular and Ductal Breast Carcinoma Differ in Immune Response, Protein Translation Efficiency and Metabolism
10.1038/s41598-018-25357-0 · 2018 · External reference
An Integrated TCGA Pan‐Cancer Clinical Data Resource to Drive High‐Quality Survival Outcome Analytics
10.1016/j.cell.2018.02.052 · 2018 · External reference
RNA Sequencing‐Based Single Sample Predictors of Molecular Subtype and Risk of Recurrence for Clinical Assessment of Early‐Stage Breast Cancer
10.1038/s41523-022-00465-3 · 2022 · External reference
The Mutational Landscape of the SCAN‐B Real‐World Primary Breast Cancer Transcriptome
10.15252/emmm.202012118 · 2020 · External reference
Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2‐Positive Breast Cancer in the NOAH Study
10.1158/1078-0432.ccr-13-0239 · 2014 · External reference
HER2 Heterogeneity and Treatment Response–Associated Profiles in HER2‐Positive Breast Cancer in the NCT02326974 Clinical Trial
10.1172/jci176454 · 2024 · External reference
SNX10 Deficiency Impairs Sensitivity to Anti‐HER2 Antibody–Drug Conjugates via Altering HER2 Trafficking in HER2‐Positive Breast Cancer
10.1073/pnas.2417586122 · 2025 · External reference
oncoPredict: An R Package for Predicting In Vivo or Cancer Patient Drug Response and Biomarkers From Cell Line Screening Data
10.1093/bib/bbab260 · 2021 · External reference
Integration of the Drug–Gene Interaction Database (DGIdb 4.0) With Open Crowdsource Efforts
10.1093/nar/gkaa1084 · 2021 · External reference
Gene Essentiality and Synthetic Lethality in Haploid Human Cells
10.1126/science.aac7557 · 2015 · External reference
High‐Resolution CRISPR Screens Reveal Fitness Genes and Genotype‐Specific Cancer Liabilities
10.1016/j.cell.2015.11.015 · 2015 · External reference
The Next‐Generation Open Targets Platform: Reimagined, Redesigned, Rebuilt
10.1093/nar/gkac1046 · 2023 · External reference
Index for Rating Diagnostic Tests
10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3 · 1950 · External reference
Trastuzumab Deruxtecan (T‐DXd) Resistance via Loss of HER2 Expression and Binding
10.1158/2159-8290.cd-25-0647 · 2025 · External reference
From CD16a Biology to Antibody‐Dependent Cell‐Mediated Cytotoxicity Improvement
10.3389/fimmu.2022.913215 · 2022 · External reference
Integrating Large‐Scale In Vitro Functional Genomic Screen and Multi‐Omics Data to Identify Novel Breast Cancer Targets
2025 · External reference
Efficacy and Safety of Neoadjuvant Pertuzumab and Trastuzumab in Women With Locally Advanced, Inflammatory, or Early HER2‐Positive Breast Cancer (NeoSphere): A Randomised Multicentre, Open‐Label, Phase 2 Trial
10.1016/s1470-2045(11)70336-9 · 2012 · External reference
Resistance Mechanisms to Anti‐HER2 Therapies in HER2‐Positive Breast Cancer: Current Knowledge, New Research Directions and Therapeutic Perspectives
10.1016/j.critrevonc.2019.05.001 · 2019 · External reference
Overcoming Resistance to HER2‐Directed Therapies in Breast Cancer
10.3390/cancers14163996 · 2022 · External reference
A Comprehensive Review of HER2 in Cancer Biology and Therapeutics
10.3390/genes15070903 · 2024 · External reference
Trastuzumab Deruxtecan Versus Treatment of Physician's Choice in Patients With HER2‐Positive Metastatic Breast Cancer (DESTINY‐Breast02): A Randomised, Open‐Label, Multicentre, Phase 3 Trial
10.1016/s0140-6736(23)00725-0 · 2023 · External reference
Highlights From the San Antonio Breast Cancer Symposium 2024
10.1159/000543369 · 2025 · External reference
Abemaciclib Plus Trastuzumab With or Without Fulvestrant Versus Trastuzumab Plus Standard‐Of‐Care Chemotherapy in Women With Hormone Receptor‐Positive, HER2‐Positive Advanced Breast Cancer (monarcHER): A Randomised, Open‐Label, Phase 2 Trial
10.1016/s1470-2045(20)30112-1 · 2020 · External reference
Neoadjuvant Treatment With Trastuzumab and Pertuzumab Plus Palbociclib and Fulvestrant in HER2‐Positive, ER‐Positive Breast Cancer (NA‐PHER2): An Exploratory, Open‐Label, Phase 2 Study
10.1016/s1470-2045(18)30001-9 · 2018 · External reference
A Multicentre Single Arm Phase 2 Trial of Neoadjuvant Pyrotinib and Letrozole Plus Dalpiciclib for Triple‐Positive Breast Cancer
10.1038/s41467-022-34838-w · 2022 · External reference
A Pilot Trial of Neoadjuvant Pyrotinib Plus Trastuzumab, Dalpiciclib, and Letrozole for Triple‐Positive Breast Cancer
10.1002/mco2.505 · 2024 · External reference
